

<b>TITLE</b>	Safety Monitoring and Reporting in Research Policy
<b>SETTING</b>	All Cabrini staff, Visiting Medical Officers (VMO's) and external collaborators engaged in research activity at Cabrini

---

## Contents

PURPOSE.....	2
DEFINITIONS .....	2
ROLES AND RESPONSIBILITIES .....	3
The Sponsor (commercial and investigator initiated) or their delegate.....	3
The Principal Investigator (PI) or their delegate.....	3
Trial Coordination Team.....	4
Cabrini Research Governance Office (CRGO) .....	4
Cabrini Research Governance Committee (CRGC) .....	4
SAFETY REPORTING POLICY .....	4
SAEs.....	4
SUSARs and USADEs .....	5
SSIs and USMs.....	5
AESIs .....	6
Safety Reporting Summary Table (*Calendar Days).....	7
NHMRC: Safety monitoring and reporting in clinical trials involving therapeutic goods (pg13) .....	9
NHMRC: Safety monitoring and reporting in clinical trials involving therapeutic goods (pg25) .....	10
REQUIREMENTS .....	11
REVIEW .....	11
REFERENCES and ASSOCIATED DOCUMENTS .....	11

## PURPOSE

To outline the procedures for the reporting and management of safety events in research at Cabrini, relating to clinical trials and other interventional studies.

## DEFINITIONS

**For clinical trials:** As defined in the NHMRC guidance: Safety monitoring and reporting in clinical trials involving therapeutic goods (2016)

<b>Investigational Medicinal Products (IMP) and Investigational Medical Devices (IMD)</b>	
Significant Safety Issue (SSI)	A safety issue that could adversely affect the safety of participants or materially impact on the continued ethical acceptability or conduct of the trial. <i>An SSI usually requires an action, such as the reporting of an urgent safety measure, an amendment, a temporary halt or an early termination of a trial.</i>
Urgent Safety Measure	A measure required to be taken in order to eliminate an immediate hazard to a participant's health or safety.
<b>Investigational Medicinal Products (IMP)</b>	
Investigational Medicinal Product (IMP)	A pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial, including a product with a marketing authorisation when used or assembled (formulated or packaged) in a way different from the approved form, or when used for an unapproved indication, a new patient group or when used to gain further information about an approved use.
Serious Adverse Event (SAE)/Serious Adverse Reaction (SAR)	Any adverse event/adverse reaction that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a congenital anomaly or birth defect.
Suspected Unexpected Serious Adverse Reaction (SUSAR)	An adverse reaction that is both serious and unexpected.
Adverse Events of Special Interest (AESI)	Adverse events of special interest (AESI) are events which are of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor may be appropriate. Such events may require further investigation to characterize and understand them. AESI's will be defined by the sponsor in the protocol as well as in the Participant Information Consent Form (PICF).
<b>Investigational Medical Devices (IMD)</b>	
Investigational Medical Device (IMD)	Medical device being assessed for safety or performance in a clinical investigation
Serious Adverse Device Effect (SADE)	An adverse device effect that has resulted in any of the consequences characteristic of a serious adverse event.
Serious Adverse Event (SAE)	An adverse event that: <ol style="list-style-type: none"> <li>a. led to death</li> <li>b. led to serious deterioration in the health of the participant, that either resulted in:               <ul style="list-style-type: none"> <li>• a life-threatening illness or injury, or</li> <li>• a permanent impairment of a body structure or a body function, or</li> <li>• in-patient or prolonged hospitalisation, or</li> </ul> </li> </ol>

	<ul style="list-style-type: none"> <li>• medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure of a body function</li> <li>c. led to fetal distress, fetal death or a congenital abnormality or birth defect.</li> </ul>
Unanticipated Serious Adverse Device Effect (USADE)	Serious adverse device effect which by its nature, incidence, severity or outcome has not been identified in the current version of the risk analysis report

## ROLES AND RESPONSIBILITIES

### The Sponsor (commercial and investigator initiated) or their delegate

- Is responsible for the ongoing safety evaluation of the investigational product.
- Is responsible for generating safety communications.
- Should evaluate all safety information that is reported by investigators as well as safety information from other sources.
- Should determine the most appropriate arrangements for ongoing monitoring and document these for Cabrini Research Governance Office (CRGO) approval.
- Should ensure all monitors comply with Cabrini's vaccination and mask requirements.
- Should ensure the protocol clearly outlines assessment and management of risk, and safety reporting parameters and responsibilities.
- Record all reported safety events.
- When communicating all safety information to investigators, CRGO and/or HRECs, must clarify the impact of each report on patient safety, trial conduct or trial documentation.
- Must assess and categorise the safety reports received from investigators, and report all suspected unexpected serious adverse reactions occurring in Australian participants to the Therapeutic Goods Administration according to the NHMRC reporting window guidelines for Australian SUSARS. Refer to *NHMRC Safety Monitoring and reporting in clinical trials involving therapeutic goods*:
  - *Appendix 1: Report Flowchart for Investigational Medicinal Product Trials*
  - *Appendix 2: Report Flowchart for Investigational Medicinal Device Trials*
- Must provide updated HREC-approved trial documentation to CRGO as soon as it becomes available, including the annual investigator's brochure update.
- Notify the TGA, HREC and investigators of all significant safety issues that adversely affect the safety of participants or materially impact on the continued ethical acceptability or conduct of the trial as per the NHMRC reporting window guidelines.

### The Principal Investigator (PI) or their delegate

- Is responsible for ensuring safety events are assessed, recorded in medical records and reported according to the study protocol and CRGO's policy. Refer to *NHMRC Safety Monitoring and reporting in clinical trials involving therapeutic goods*:
  - *Appendix 1: Report Flowchart for Investigational Medicinal Product Trials*
  - *Appendix 2: Report Flowchart for Investigational Medicinal Device Trials*
- Should provide the sponsor with all relevant information so that an appropriate safety analysis can be performed.
- Should capture and assess all safety events that occur at Cabrini in accordance with the protocol

- Should report to the sponsor any safety events (as defined by the protocol) and USM's instigated at Cabrini to the sponsor within 24 hours of becoming aware of the event;
- Should report any SAEs/SSI and SUSARs arising at Cabrini to the CRGO within 72 hours of becoming aware of the event
- Can delegate trial duties to qualified individuals as long as they possess the requisite training, education and experience to fulfil this role. Delegation must be recorded in the study's delegation and training logs. The PI remains ultimately responsible for any decision made by their delegate.
- Where the assessment of a SUSAR's causality differs between the Sponsor and the PI, the opinions of both the PI and the sponsor should be provided with any SUSAR report sent to the TGA.

### **Trial Coordination Team**

- Facilitates Cabrini's approved requirements for safety monitoring visits
- Ensures monitors meet Cabrini's vaccination requirements and mask mandates
- Is responsible for supporting the PI, AI's and delegated staff in preparing and submitting safety reporting

### **Cabrini Research Governance Office (CRGO)**

- Receives safety reports for any SAE's, SSIs and SUSARs occurring at Cabrini, and coordinates review and executive oversight via the Cabrini Research Governance Committee (CRGC).
- Maintains a risk management register of all reportable safety events.

### **Cabrini Research Governance Committee (CRGC)**

- Reviews reportable safety events, incidents and risks occurring at the Cabrini, and determines referral via the organisation's risk management policy
- Supports Academic Research Department Heads:
  - In developing and implementing strategies for risk management in their area of responsibility
  - To inform Executives, via the CRGC, of the high risks and propose risk treatment strategies
  - To escalate risk issues to the Executives, via the CRGC, where appropriate

## **SAFETY REPORTING POLICY**

Cabrini Research endorses and adopts the NHMRC Guidance: Safety monitoring and reporting in clinical trials involving therapeutic goods (2016).

### **SAEs**

Sponsors are required to

- keep detailed records of all reported SAEs and maintain up-to-date tabulations and/or line listings
- assess and categorise the safety reports received from investigators
- Submit any safety related changes to trial documentation to the HREC without undue delay. These HREC-approved amendments must be shared with the investigators to seek CRGO governance approval.

The PI or their delegate is required to:

- capture and assess all SAEs that occur at Cabrini as required and in accordance with the protocol
- report to the sponsor within **24 hours** of becoming aware of the event:
  - all SAEs, except those that are identified in the protocol as not needing immediate reporting
  - any occurrences of congenital anomaly/birth defect arising from any pregnancy of a participant (or partner)
  - all urgent safety measure instigated by the Cabrini PI (or their delegate)
- Share any HREC-approved updated trial documentation resulting from the safety events for CRGO approval.

### SUSARs and USADEs

The sponsor is required to report all SUSARs and USADEs occurring in Australian participants to the Therapeutic Goods Administration (TGA)

- for fatal or life threatening Australian SUSARs, immediately, but no later than **7 calendar days** after being made aware of the case, with any follow-up information within a further **8 calendar days**
- for all other Australian SUSARs/USADEs, no later than **15 calendar days** after being made aware of the case

The sponsor must submit any safety related changes to trial documentation to the HREC without undue delay. These HREC-approved amendments must be shared with the investigators to seek CRGO approval. The Principal Investigator is required to report SUSARs/USADEs occurring at Cabrini to the CRGO within **72 hours** of becoming aware of the event. SUSARs occurring at external sites should not be reported to CRGO unless they are deemed by the sponsor to be an SSI.

### SSIs and USMs

SSI's usually require other action, such as the reporting of a USM, an amendment, a temporary halt or an early termination of a trial. In addition, SSIs often result in safety-related changes to trial documentation. These amendments should be submitted to the HREC without undue delay. These HREC-approved amendments must be shared with the CRGO for approval.

USMs are one type of SSI where sponsors or trial investigators act immediately to protect participants from an immediate hazard to their health and safety. Consequently, USMs are often instigated before the TGA and HREC are notified. In these cases, it is strongly recommended that the sponsor contact the TGA within **24 hours** of the measure being taken.

The sponsor is required to notify the TGA, HREC and investigators of all significant safety issues that adversely affect the safety of participants or materially impact on the continued ethical acceptability or conduct of the trial for:

- SSI's that meet the definition of a USM should be notified within **72 hours**
- all other significant safety issues should be notified within **15 calendar days** of the sponsor instigating or being made aware of the issue.

The PI or their delegate is required to:

- Report all SSI's to the CRGO within **72 hours** of becoming aware of the event; and
- Report USM's instigated by the site to the sponsor within **24 hours** of becoming aware of the event

## AESIs

The PI or their delegate is responsible for determining whether an AESI qualifies for reporting to the CRGO however should ultimately be guided by the reporting requirements of the study protocol. AESIs are not reviewed by HRECs.

### CRGO safety reporting guidelines:


- CRGO will accept the Victorian Government’s Safety Report Form (December 2017), Sponsor Safety Report Templates and CIOMS forms. All forms must provide commentary on how the investigator determined the event is related to the investigational product and the health status of the patient at the time of reporting.
- Reports must contain no participant identifiers.
- The PI or their delegate can report any events to the CRGO, the Sponsor or the HREC based on their clinical assessment and opinion, even if the event may not meet the reporting criteria stipulated in the protocol and NHMRC guidance, or if the opinion is not supported by the sponsor.
- Reports are not required by the CRGO if the safety event is not related to the IMP or IMD, or is due to disease progression. If, however, it is related to a clinical incident or near miss at Cabrini, then reporting is required in RiskMan™ as per Cabrini’s Incident Management Policy and Procedures.
- Grade 3+ safety events must be reported in the Cabrini Research Risk Register.
- An email to [researchgovernance@cabrini.com.au](mailto:researchgovernance@cabrini.com.au) to notify the CRGO of a SUSAR, SAE/SSI or USM as soon as it happens in a Cabrini cohort is encouraged.
- If multiple follow-up reports are provided, only those that provide new and useful information that enables meaningful analysis and/or changes perspectives on how the event should be assessed or managed should be presented to the CRGC.
- Development Safety Update Reports (DSURs) executive summaries, line listings, or other periodic safety reports do not require submission to CRGO. The DSUR executive summary can be submitted if the investigator and sponsor feel there is an impact on the conduct of the study.

### Safety Reporting Summary Table (\*Calendar Days)


Event	Resp.	Action	Reporting Window	Tool
SAE, SADE	Sponsor	<ul style="list-style-type: none"> <li>keep records of all reported events</li> <li>maintain up-to-date tabulations / line listings</li> <li>assess and categorise the safety reports from PIs</li> </ul>	N/A	N/A
	PI or delegate	<p>Capture and assess all Cabrini events in accordance with the protocol and report to the sponsor:</p> <ul style="list-style-type: none"> <li>all events the protocol mandates for immediate reporting</li> <li>occurrences of congenital anomaly/birth defect arising from any pregnancy of a participant (or partner)</li> <li>all urgent safety measure instigated by the Cabrini PI</li> </ul> <p>Report all Cabrini events to the CRGO that are potentially or definitely related the IMP/IMD (not disease progression), assessed as a severity grade 3+ (hospitalisation), and may have an impact on the conduct of the study.</p>	<p>Within <b>24hrs</b> of becoming aware of event</p> <p>Within <b>72hrs</b> of becoming aware of event</p>	Vic Govt safety / sponsor / CIOMS forms
SUSARs USADEs	Sponsor	<p>Report Australian events to the TGA</p> <ul style="list-style-type: none"> <li>fatal or life-threatening Australian events</li> <li>for all other Australian events</li> </ul>	<p>Immediately, but no more than <b>7* days</b> after becoming aware of event, follow-up info within a further <b>8* days</b></p> <p>no more than <b>15* days</b> after becoming aware of event</p>	<a href="#">Refer to TGA sponsor regulatory reporting requirements page</a>
	PI or delegate	<p>Report Cabrini events to the CRGO</p> <p>Report external (non-Cabrini) events only if they have been deemed by the sponsor to be an SSI.</p>	<p>Within <b>72hrs</b> of becoming aware of the event.</p> <p>Within <b>72hrs</b> of becoming aware of the event.</p>	Vic Govt safety / sponsor / CIOMS forms
SSI, USM	Sponsor	<ul style="list-style-type: none"> <li>Alert the TGA of any USMs <i>instigated before the TGA and HREC were notified</i></li> <li>Notify the TGA, HREC and PIs of SSI's that meet the definition of a USM</li> <li>Notify the TGA, HREC and PIs of all other significant safety issues</li> </ul>	<p>Within <b>24hrs</b> of the measure being taken</p> <p>Within <b>72hrs</b> of becoming aware of the issue</p> <p>Within <b>15* days</b> of instigating or becoming aware of the issue</p>	<a href="#">Refer to TGA sponsor regulatory reporting requirements page</a>

	PI or delegate	<ul style="list-style-type: none"> <li>Report all SSI's to the CRGO</li> <li>Report USM's instigated by the Cabrini PI to the sponsor and CRGO</li> </ul>	<p>Within <b>72hrs</b> of becoming aware of the event</p> <p>Within <b>24hrs</b> of becoming aware of the event</p>	Vic Govt safety / sponsor / CIOMS forms
AESI	PI or delegate	<ul style="list-style-type: none"> <li>Report to sponsor as per protocol.</li> <li>Report to CRGO if the PI deems it necessary.</li> </ul>	<p>As per protocol</p> <p>PI's judgement</p>	Sponsor form

## Appendix 1: Report Flowchart for Investigational Medicinal Product Trials



## Appendix 2: Reporting Flowchart for Investigational Medical Device Trials



## REQUIREMENTS

Victorian State Government Safety Report Form

## REVIEW

This policy should be reviewed every 3 years or sooner if in response to national and state regulatory changes.

## REFERENCES and ASSOCIATED DOCUMENTS

[Integrated Addendum to ICH E6\(R1\): Guideline for Good Clinical Practice ICH E6\(R2\)](#)  
[NHMRC Safety monitoring and reporting in clinical trials involving therapeutic goods](#)  
[Clinical Incident Management Policy and Procedures](#)  
[Risk Management](#)

## Key Legislation and Standards

[National Clinical Trials Governance Framework](#)

## ACKNOWLEDGEMENTS

Monash Health Research Ethics and Governance Safety Reporting Procedure  
Epworth Management and Reporting of Safety Events  
Alfred Health Safety Monitoring & Reporting

## REVISION HISTORY

Version	Revision date	Revision notes
1.0	1 September 2023	New document

<b>Executive Sponsor</b>	<b>Group Director Cabrini Research</b>	
<b>Approved By:</b>	<b>Cabrini Research Governance Committee</b>	<b>Date: 3 August 2023</b>
<b>Authorised By:</b>	Clinical Policy Committee	<b>Date: 1 September 2023</b>